
The Danish biotech company Zealand Pharma continues to thrill investors. As expected, the company is now initiating the first clinical study with its candidate drug ZP2929 for type II diabetes and obesity.
The candidate, which had previously only been tested on animals, has already been administered to the first human test subject, according to a stock market release. It triggers a milestone payment of DKK 37 million from Zealand’s partner, the German pharmaceutical giant Boehringer Ingelheim.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app